Canada markets open in 4 hours 28 minutes

Creso Pharma Ltd. (1X8.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
0.0237-0.0001 (-0.42%)
As of 08:04AM CEST. Market open.
Full screen
Previous Close0.0238
Bid0.0239 x 0
Ask0.0254 x 0
Day's Range0.0237 - 0.0237
52 Week Range0.0237 - 0.1000
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

    Halucenex to receive recently harvested first batch of psilocybe cubensis Optimi Head of Cultivation, Todd Henderson Optimi Head of Cultivation, Todd Henderson, navigates Optimi's new fruiting chamber. Psilocybin Cubensis Optimi psilocybin cubensis (liquid culture). VANCOUVER, British Columbia, May 27, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom f

  • CNW Group

    Sierra Sage Herbs Acquired By Creso Pharma

    Sierra Sage Herbs, maker of the best-selling Green Goo, Southern Butter and Good Goo natural products brands, announced today its acquisition by Australia's Creso Pharma Limited (ASX: CPH, OTC: COPHF, FRA: 1X8). The deal extends Creso's global footprint to the US market while adding an additional range of natural health products to its existing lines of cannabis and hemp-based pharmaceuticals. Sierra Sage, which counts 90,000 points of distribution across the US including Whole Foods, Walmart, A

  • Business Wire

    SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

    WATERTOWN, Mass., December 09, 2021--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented interim results from the highest-dose cohort of its ongoing Phase 1/2 clinical trial of lead Antigen Presenting Cell (APC) therapy candidate targeting Human Papillomavirus positive (HPV16+) solid tumors at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress. Of the five patients in this cohort eva